Salt Lake City, United States
Biolexis Therapeutics, Inc., founded in 2021 and based in the United States, is on the cutting edge of pharmaceutical innovation with its revolutionary Moleculern™ technology, which is poised to transform the drug discovery landscape. Their motto, "Accelerating Drug Discovery," is a testament to their mission of developing better, safer drugs more efficiently.
Leveraging a unique chemical biology approach coupled with advanced machine learning and AI, Biolexis processes over 600k empirical data points to identify promising drug candidates swiftly. This platform accelerates the creation of novel chemical entities (NCEs) by mapping critical hot-spots and computing ligand properties.
Recently, Biolexis secured a $10.00M Series A investment from Clarke Capital Group on 01 November 2023. This funding will further empower their mission to expedite drug development pathways, potentially transforming pre-clinical compounds into first-in-human (FIH) trials and hastening the delivery of new therapeutics to patients worldwide.
